newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

  • Cogent Biosciences plans dual launches of bezuclastinib for Systemic Mastocytosis & Gastrointestinal Stromal Tumors in the second half of 2026.
  • Pivotal Phase 3 PEAK trial data for bezuclastinib in GIST will be presented at the 2026 ASCO annual meeting.
  • The company ended Q1 2026 with $866.4 million in cash, sufficient to fund operations through 2028.
  • The FDA accepted the NDA for bezuclastinib in NonAdvanced Systemic Mastocytosis with a PDUFA target date of December 30, 2026.
  • Cogent submitted an NDA for bezuclastinib in GIST under the FDA's Real-Time Oncology Review program after positive PEAK trial results.
  • The company anticipates submitting an NDA for Advanced Systemic Mastocytosis in the first half of 2026.
  • Research & development expenses rose to $75.4 million in Q1 2026 from $63.0 million the prior year.
  • General & administrative expenses increased to $28.2 million in Q1 2026 from $11.9 million the prior year.
  • Net loss for Q1 2026 was $97.4 million compared to $72.0 million in Q1 2025.
  • The firm initiated Phase 1 studies for novel ErbB2 & PI3Kα inhibitors CGT4255 & CGT6297.
  • Cogent announced inducement equity awards for seven new employees on April 29, 2026.